Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab plus moderate-intensity statin versus high-intensity statin for acute ischemic stroke caused by symptomatic intracranial atherosclerotic stenosis
ChiCTR2300069104Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in ischemic stroke, Cerebral atherosclerotic stenosis (ICAD) and Ischaemic cerebral disease (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoints: LDL-C value, Internal carotid atherosclerotic plaque size and 2 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic strokeCerebral atherosclerotic stenosis (ICAD)Ischaemic cerebral disease
Beyond the preview
Go deeper on ChiCTR2300069104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069104.